One of the most dreaded feelings for an investor is when the stock they just bought is overvalued, or they missed out on an undervalued opportunity by not acting fast enough.

But what if you had the insights to effectively evaluate a company like Reata Pharmaceuticals Inc before investing? Investing requires a certain perspective to avoid being overly confident in a company or worried about cyclical changes. A smart way to take the guesswork out of knowing when to buy or sell Reata Pharmaceuticals Inc’s stock is to have the right tools and resources as well as a clear monitoring process.

In this article, we go over a few key elements for understanding Reata Pharmaceuticals Inc’s stock price such as:

• Current stock price and volume
• Stock price history
• Upgrades and downgrades from analysts
• Stock price momentum as measured by its relative strength

About Reata Pharmaceuticals Inc (RETA)

Before we jump into Reata Pharmaceuticals Inc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on identifying, developing, and commercializing therapies. The Company is also focused on providing small-molecule therapeutics with mechanisms of action for the treatment of severe, life-threatening diseases with therapies. Its lead programs are omaveloxolone in a neurological disease called Friedreich’s ataxia (FA) and bardoxolone methyl (bardoxolone) in rare forms of chronic kidney disease (CKD). The Company’s lead product candidates activate the transcription factor Nrf2 to normalize mitochondrial function, restore redox balance, and resolve inflammation. It is also developing RTA 901, the lead product candidate from its Hsp90 modulator program, in neurological indications. Omaveloxolone and bardoxolone are Nuclear factor-erythroid factor 2-related factor 2 (Nrf2) activators that selectively bind to Keap1, a protein that governs the activity of Nrf2 in response to cellular stress.

Want to learn more about Reata Pharmaceuticals Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Reata Pharmaceuticals Inc. The AAII Stock Evaluator puts a company’s grades, charts, news, financials, valuation, ratios, filings and more at your fingertips.

Reata Pharmaceuticals Inc’s Stock Price as of Market Close

As of February 24, 2023, 4:00 PM CST, Reata Pharmaceuticals Inc’s stock price was $44.51.

Reata Pharmaceuticals Inc is down 11.77% from its previous closing price of $50.45.

During the last market session, Reata Pharmaceuticals Inc’s stock traded between $45.61 and $50.47. Currently, there are 36.54 million shares of Reata Pharmaceuticals Inc stock available for purchase.

Unfortunately, Reata Pharmaceuticals Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Reata Pharmaceuticals Inc Stock Price History

Reata Pharmaceuticals Inc’s (RETA) price is currently up 2.72% so far this month.

During the month of February, Reata Pharmaceuticals Inc’s stock price has reached a high of $51.98 and a low of $37.80.

Over the last year, Reata Pharmaceuticals Inc has hit prices as high as $51.98 and as low as $18.47. Year to date, Reata Pharmaceuticals Inc’s stock is up 68.79%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Reata Pharmaceuticals Inc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of February 23, 2023, there were 4 analysts who downgraded Reata Pharmaceuticals Inc’s stock and 3 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Reata Pharmaceuticals Inc’s financial health and valuation. It is possible for a stock to appear cheap based on one valuation metric but appear expensive on another. It is also possible for one valuation ratio to be associated with outperforming stocks during certain periods of time but not others.

Therefore, AAII developed a composite valuation to help resolve such issues. AAII’s Value Grade analyzes six distinct variables: price-to-sales (P/S) ratio, price-earnings (P/E) ratio, the ratio of enterprise value to earnings before interest, taxes, depreciation and amortization (EV/EBITDA), shareholder yield, price-to-book-value (P/B) ratio and price-to-free-cash-flow (P/FCF) ratio.

Reata Pharmaceuticals Inc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Reata Pharmaceuticals Inc (RETA) by visiting AAII Stock Evaluator.

Relative Price Strength of Reata Pharmaceuticals Inc

Relative price strength addresses the relationship between a stock price’s trend and the price trend of the market. This ratio is expressed as a percentage and helps investors understand a company’s momentum as well as its value. You can use relative price strength to select investments that have been outperforming the market or a specific benchmark.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. The weighted four-quarter relative price strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40%, and each of the three previous quarters are given a weighting of 20%.

As of February 23, 2023, Reata Pharmaceuticals Inc has a weighted four-quarter relative price strength of 27.85%, which translates to a Momentum Score of 96 and is considered to be Very Strong.

Want to learn more about how Reata Pharmaceuticals Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Reata Pharmaceuticals Inc Stock Price: Bottom Line

As of February 24, 2023, Reata Pharmaceuticals Inc’s stock price is $44.51, which is down 11.77% from its previous closing price.

At AAII, we stress that investors should never buy or sell a stock solely based on its stock price. Past returns do not guarantee future performance. Therefore, you should consider multiple ratios, fundamentals and analytics before making a decision. Whether you decide it’s a good time to buy or sell Reata Pharmaceuticals Inc’s stock based on its stock price forecast is ultimately up to you.

It’s important to understand that stock prices are driven by a variety of factors, but ultimately the price at any given moment is due to the supply and demand in the market. Stock price overviews, like the one you just read, only give you a small snapshot of a company’s performance, value and momentum.

By becoming an A+ Investor subscriber, you will have full access to analytics, grades, stock screens, commentary and more so you can invest with confidence.